Wites Law Firm is announcing their investigation of BioScrip, Inc. (“BioScrip” or the “Company”)(Nasdaq: BIOS) and a possible class action lawsuit which may allege that the Company and certain of its officers and directors committed violations of the Securities Exchange Act of 1934. On September 23, 2013, BioScrip disclosed in a Securities and Exchange Commission (SEC) Form 8-K filing that the Company received a civil investigative demand issued by the United States Attorney’s Office for the Southern District of New York and a subpoena from the New York State Attorney General’s Medicaid Fraud Control Unit regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade® by the Company’s legacy specialty pharmacy division. Following this news, BioScrip’s common stock declined in price by 6% to close at $10.41 per share on September 23, 2013. The next trading day, September 24, 2013, BioScrip’s common stock declined more than 18% to close at $8.47 per share. A securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors who purchased shares of BioScrip’s common stock during the period between August 8, 2011 and September 20, 2013, inclusive (the “Class Period”). The deadline for filing for lead plaintiff is November 29, 2013.
If you are an investor who purchased BioScrip common stock between August 8, 2011 and September 20, 2013, you may have a legal claim against the Company and could serve as the lead plaintiff in the case. If you are interested in being the lead plaintiff, or would like to speak with an attorney about your legal rights, contact the attorneys at Wites Law Firm by email at email@example.com or toll-free at 1 (866) 277-8631.
Wites Law Firm, is a law firm with offices in Oakland, California and Lighthouse Point, Florida, with expertise in the representation of investors in securities fraud and investor litigation claims. You may visit its website atwww.wklawyers.com.